Table III.
Clinical trials investigating CAR T cell therapy with checkpoint blockade in Glioblastoma
| ClinicalTrials.gov Code | Phase study | Checkpoint inhibition strategy | CAR T cell | Malignancy | Sample size |
|---|---|---|---|---|---|
| NCT03726515 | Phase I | CAR T cell plus αPD-1 mAb Pembrolizumab | EGFRvIII CAR |
EGFRvIII+ Glioblastoma | 7 |
| NCT04003649 | Phase I | CAR T cell plus αPD-1 mAb Nivolumab and αCTLA-4 Ipilimumab | IL-13Rα2 CAR |
IL-13Rα2+ Glioblastoma | 60 |
| NCT02873390 | Phase I/II | CAR T cell expressing αPD-1 mAb | EGFR CAR |
EGFR+ cancers | 20 |
| NCT03182816 | Phase I/II | CAR T cell expressing αPD-1 mAb and αCTLA-4 | EGFR CAR |
EGFR+ cancers | 40 |